GYKI-52895

GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor,[1][2] which presumably would produce stimulant effects in vivo. Its DRI activity is shared by numerous addictive drugs including amphetamine and its derivatives (e.g. dextromethamphetamine), cocaine, and methylphenidate and its derivatives (e.g. ethylphenidate). However, dopaminergic drugs are also prone to producing emetic effects such as in the case of apomorphine.

GYKI-52895
Clinical data
Other names4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC17H17N3O2
Molar mass295.34 g/mol g·mol−1
3D model (JSmol)
  (verify)

See also

References
  1. Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F. Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor. European Journal of Pharmacology. 1990; 183(4):1416-1417.
  2. Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, Lai HL, Chern Y. Modulation of Dopamine Transporter Activity by Nicotinic Acetylcholine Receptors and Membrane Depolarization in Rat Pheochromocytoma PC12 Cells. Journal of Neurochemistry. 1999; 72(6): 2437–2444.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.